louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01567241: Clinical Hypnosis During Insemination or Embryotransfer
Official title: Prospective Off-center Randomised Trial of Clinical Hypnosis Versus Relaxation Music
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Reproduction Dysfunction
Keywords: clinical hypnosis
relaxation music
reproduction techniques
insemination
embryo transfer
pregnancy rate
Lead sponsor: Johann Wolfgang Goethe University Hospital
Sponsor class: OTHER
First posted: 2012-03-30
Enrollment: 282
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Does clinical hypnosis or relaxation music improve the pregnancy rate if reproduction techniques are required?


Eligibility criteria: Inclusion Criteria:

Planned insemination or embryo transfer

Exclusion Criteria:

under age not able to understand German

Primary outcomes:
measure: Pregnancy rate
timeFrame: 4 weeks after insemination / embryotransfer
Secondary outcomes:
measure: Questionnaire: Intervention rating
timeFrame: 5 minutes before and 5 minutes after insemination / embryotransfer
Other outcomes:
Locations:
city: Frankfurt
country: Germany
facility: Klinik für Frauenheilkunde und Geburtshilfe
state: Hessen
Study officials:
affiliation: Goethe University
name: Joscha Reinhard, Priv-Doz. Dr. med. MBBS BSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06343441: Accuracy of Two Methods of Making Impressions for Complete-arch Implant Supported Fixed Prosthesis
Official title: A Randomized Controlled, Double-blind Clinical Trial to Evaluate the Clinical Effectiveness of Two Methods of Taking Impressions for an Implant-supported Fixed Prostheses With One-piece Titanium Frameworks in Edentulous Jaws
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Edentulous Jaw
Lead sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Sponsor class: OTHER
First posted: 2024-04-02
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the accuracy of digital impression and conventional impression for complete-arch implant-supported fixed prosthesis

Detailed description: The Intraoral scan is digital optical scan method, that has advantages such as being more comfortable, easy to transfer, and full digital workflow. Conventional impression using silicon rubber and gained stable accuracy of impression. This study aims to compare the accuracy of two methods.

Eligibility criteria: Inclusion Criteria:

* Age 18-70 years old (including 18 and 70 years old);
* The patient's maxilla or mandible cannot be preserved due to missing teeth or remaining teeth proposed for implant-retained restoration;
* The patient's missing teeth area is available for placement of 4-6 implants;
* Completion of osseointegration of the patient's implants after implant surgery;
* The patient has at least 2 mm width of keratinized mucosa in the remaining alveolar ridge;
* The patient voluntarily participates in the trial and signs an informed consent form

Exclusion Criteria:

* The patient has a severe gag reflex;
* The patient has an intermaxillary distance of less than 20 mm in the posterior region;
* The distance between the two implants is less than 10 mm;
* Implants fitted with composite abutments with the abutment screw holes penetrating at an angle greater than 60 degrees to the alveolar ridge;
* Other patients judged by the investigator to be unsuitable for inclusion

Primary outcomes:
measure: Grade of framework passive fit
timeFrame: during the deliver of the framework
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06208241: Use of Allocetra-OTS in End Stage Knee Osteoarthritis - Assessment of Safety
Official title: Use of Allocetra-OTS in End Stage Knee Osteoarthritis - Assessment of Safety
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: EARLY_PHASE1
Conditions: Knee Osteoarthritis
Lead sponsor: Kaplan Medical Center
Sponsor class: OTHER
Collaborators: name: Enlivex Therapeutics Ltd.
First posted: 2024-01-17
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a pilot study to assess safety and possible efficacy of Allocetra-OTS in end-stage knee osteoarthritis.


Eligibility criteria: Inclusion Criteria:

1. Age 18 or older.
2. Diagnosed with end-stage knee osteoarthritis and are scheduled or offered surgery.
3. X-ray positive for knee osteoarthritis.
4. Pain and functional disability from osteoarthritis.
5. Accetable blood workup results (CBC, electrolytes, kidney and liver function) from up to three months before treatment.
6. Mentally and physically able to fully comply with the study protocol.
7. Signed Informed Consent form.

Exclusion Criteria:

1. Evidence of active local infection in the vicinity of the knee joint.
2. Previous surgery of total or partial knee replacement in the injected knee.
3. Patients unable to provide informed consent due to language barrier or mental status.
4. Patients with a major medical condition that would affect quality of life and influence the results of the study.
5. Patients unwilling to be followed for the duration of the study.
6. Acute infection requiring intravenous antibiotics at the time of screening.
7. Other limb pain of unknown etiology.
8. Pain in the limb clinically assessed to arise from an origin which is not the affected knee joint.
9. Known neurological disease or rheumatic condition other than osteoarthritis.
10. Bleeding disorders.
11. Known cognitive disorder.
12. Concurrent participation in any other clinical study. Participation in an interventional investigational study within 30 days prior to enrollment.
13. Physician objection.
14. Positive pregnancy test.

Primary outcomes:
measure: Treatment-emergent adverse events and Serious adverse events following Allocetra-OTS injection
timeFrame: 6 months
Secondary outcomes:
measure: Efficacy of Allocetra-OTS- Pain mitigation as measured by Visual Analog Scale tool.
timeFrame: 6 months
measure: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) response change along study period
timeFrame: 6 month
measure: SF-36 questionnaire response change along study period
timeFrame: 6 month
Other outcomes:
Locations:
city: Reẖovot
country: Israel
facility: Kaplan Medical Center
Study officials:
affiliation: Kaplan Medical Center
name: Amir Oron, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02550041: Analysis T Cells Response for Identification of Aspergillus Bronchitis With Cystic Fibrosis Patients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Cystic Fibrosis Patient
Patient Without Treatment Against A.Fumigatus
Keywords: Bronchitis aspergillus
cystic fibrosis
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2015-09-15
Enrollment: 68
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The study aims to asses the ability of cell tests based on the analysis of the anti-Aspergillus cell responses and identify Aspergillus bronchitis with patients with cystic fibrosis.

In addition, the study will evaluate the contribution of biological classification of aspergillosis according to criteria recently proposed by Baxter et al. compared to the classification used in clinical practice in the hospital of Montpellier.


Eligibility criteria: Inclusion Criteria:

* Patient with cystic fibrosis followed at Resource Centers and Cystic Fibrosis Skills (CRCM) Montpellier
* Patient aged 15 or over
* Patient able to understand the nature, purpose and methodology of the study.
* Patient and his legal representative for minors who have given their free and informed consent
* Affiliate or beneficiary of a social security scheme.

Exclusion Criteria:

* Patients on antifungal treatment at the time of sampling
* Pregnant or breastfeeding
* Major protected by law (guardianship, curator or under Backup Justice)
* Inability to understand the nature and goals of the study and / or communication difficulties with the investigator
* Subject attending another search including a period of exclusion still going to run-in

Primary outcomes:
measure: Number of CD4 T cell response against Aspergillus fumigatus in patients with cystis fibrosis
timeFrame: 12 months
measure: Cytokine level of TCD8
timeFrame: 12 months
measure: Cytokine level CD4 cells
timeFrame: 12 months
Secondary outcomes:
measure: Level of fumigatus specific IgE
timeFrame: 12 months
measure: Level of fumigatus specific IgG
timeFrame: 12 months
measure: Real-time PCR for aspergillus in sputum
timeFrame: 12 months
measure: Galactomannan by enzyme immune assay detection in sputum
timeFrame: 12 months
measure: Levels of cytokine (IFNg, IL10, IL4 and TNF) evaluated by flow cytometry
timeFrame: 12 months
measure: Level of IL10 evaluated by Elispot dedicated to anti-aspergillus CD4 T cells
timeFrame: 12 months
measure: Flow cytometry techniques dedicated to anti-aspergillus CD4 T cell assessment
timeFrame: 12 months
measure: Level of IFNg evaluated by Elispot dedicated to anti-aspergillus CD4 T cells
timeFrame: 12 months
measure: Elispot dedicated to anti-aspergillus CD4 T cell
timeFrame: 12 months
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Irmb/U1058
Study officials:
References:
Clinical trial NCT07025941: Impact of Comprehensive Rehabilitation Nursing Combined With Refined Airway Management and Nutritional Support on Prognosis and Care Delivery Models in Critically Ill Patients
Official title: Impact of Comprehensive Rehabilitation Nursing Combined With Refined Airway Management and Nutritional Support on Prognosis and Care Delivery Models in Critically Ill Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Critically Ill Patients
Nutritional Support
Pulmonary Infections
Gastrointestinal Bleeding
Acute Kidney Injury (AKI)
Lead sponsor: Taizhou Hospital of Traditional Chinese Medicine
Sponsor class: OTHER_GOV
First posted: 2025-06-18
Enrollment: 101
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This combined intervention protocol effectively improves the prognosis of critically ill patients and optimizes nursing management models

Detailed description: To investigate the impact of comprehensive rehabilitation nursing combined with refined airway management and nutritional support on the prognosis of critically ill patients and nursing management models, and to develop a new care management protocol. Critically ill patients were divided into a control group (routine nursing) and an intervention group (comprehensive rehabilitation nursing combined with refined airway management and nutritional support). Complications such as pulmonary infection and gastrointestinal bleeding, as well as clinical indicators including oxygen saturation (SpO₂), mechanical ventilation time (MVT), and length of stay (LOS), were compared between the two groups. Logistic regression and XGBoost models were constructed to analyze key influencing factors.

Eligibility criteria: Inclusion Criteria:

* Fulfillment of ICU admission standards with critical illness confirmed by attending physicians or senior specialists
* Age ≥ 18 years
* Stable vital signs:

Systolic blood pressure ≥ 90 mmHg and ≤ 180 mmHg

Heart rate ≤ 120 beats/min

Oxygen saturation (SpO₂) ≥ 85% under ≤ 60% fraction of inspired oxygen (FiO₂)

* Intact or tolerable gastrointestinal (GI) function for enteral nutrition
* Informed consent from both patients and families Exclusion Criteria:(1)
* Terminal malignancies
* Brain death
* Irreversible organ failure (e.g., end-stage cirrhosis, advanced heart failure)
* Comorbidities potentially confounding study outcomes
* Contraindications to interventions (e.g., laryngeal edema, complete intestinal obstruction)
* Pregnancy or lactation

Primary outcomes:
measure: ICU Length of Stay (LOS)
timeFrame: From randomization to ICU discharge, up to 60 days
Secondary outcomes:
measure: Incidence of Pulmonary Infections
timeFrame: From ICU admission to 48 hours post-extubation or 14-day intervention period
Other outcomes:
measure: Protocol Adherence Rate
timeFrame: Daily during 14-day intervention
Locations:
city: Taizhou
country: China
facility: Taizhou Hospital of Traditional Chinese Medicine
state: Jiangsu
Study officials:
References:
Clinical trial NCT02141841: Effect of Age on the Median Effective Concentration(EC50) for Motor Block With Spinal Plain Bupivacaine
Official title: Effect of Age on the Median Effective Concentration(EC50) for Motor Block With Spinal Plain Bupivacaine
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Mononeuropathy of the Median Nerve, Mild
Keywords: intrathecal;
bupivacaine;
concentration;
Lead sponsor: China Three Gorges University, Yichang, China
Sponsor class: OTHER
First posted: 2014-05-20
Enrollment: 0
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This study was performed in 131 adult patients undergoing transurethral, urological or lower limb surgery under combined spinal and epidural anesthesia.

Brief summary: This study was performed in 131 adult patients undergoing transurethral, urological or lower limb surgery under combined spinal and epidural anesthesia. Patients were stratified according to age: 20-30, 31-40, 41-50, 51-60, 61-70, and 71-80 years. The spinal component of the anesthetic was established by bolus administration of up-and-down doses of 0.75% plain bupivacaine, determined by Dixon's method. The degree of motor block after intrathecal administration of each concentration was evaluated by the modified Bromage and Hip motor function score. The EC50 were estimated from the up-and-down sequences using the method of Dixon and Massey and logistic regression. Other endpoints were included on the basis of sensory block level, duration of motor blockade, hypotension, and vasopressor requirements.


Eligibility criteria: Inclusion Criteria:

- ASA physical status I-II adult patients who were undergoing transurethral, urological or lower limb surgery, primarily under the spinal component of established combined epidural-spinal anesthesia, with the epidural component to be used if there was a need for intra-operative analgesic supplementation or for postoperative analgesia.

Exclusion Criteria:

* Patients with diabetes, obesity, neuromuscular diseases, bleeding diathesis, hypersensitivity to amide local anesthetics, lumbar vertebrae abnormality, chronic back pain, or who were pregnant were excluded from this study

Primary outcomes:
measure: the median effect concentration of bupivacaine
timeFrame: The endpoint was determined according to the degree of motor power in any lower limb (according to the modified Bromage scale and the Hip motor function scale) within 5 minutes after intrathecal administration of the tested bupivacaine concentration
measure: sensory block level
timeFrame: 20 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Yichang
country: China
facility: China Three Gorges University
state: Hubei
Study officials:
References:
Clinical trial NCT05423041: A Prospective Clinical Trial Designed to Evaluate the Repeatability and Reproducibility of the Intelon BOSS(tm) System
Official title: Prospective Clinical Trial Designed to Evaluate the Repeatability and Reproducibility of the Intelon BOSS(tm) System
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Corneal Transplant
Corneal Crosslinking
Healthy Eyes
Lead sponsor: Intelon Optics, Inc
Sponsor class: INDUSTRY
First posted: 2022-06-21
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is a prospective, open-label, single-site clinical trial designed to evaluate the repeatability and reproducibility of biomechanical imaging by the updated version of the BOSS device. Subjects will undergo unilateral biomechanical mapping of the cornea and lens by three (3) BOSS devices operated by three (3) different operators.


Eligibility criteria: Inclusion Criteria:

* 18 years or older

Exclusion Criteria:

* No light perception
* Any systemic disease or disorder which would prohibit image aquisition

Primary outcomes:
measure: Analysis of variance in BOSS analysis to determine repeatability and reproducibility
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Fayetteville
country: United States
facility: Vold Vision plc
state: Arkansas
Study officials:
References:
Clinical trial NCT05044741: Risk Factors of Perforated HSCR in Neonates
Official title: The Risk Factors for Bowel Perforation in Neonates With Hirschsprung Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hirschsprung Disease
Bowel; Perforation, Fetus or Newborn
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
Collaborators: name: Wuhan Children's Hospital
name: The First Affiliated Hospital of Zhengzhou University
First posted: 2021-09-16
Enrollment: 600
Sex: ALL
Minimum age (years): 0
Maximum age (years): 30
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: -Neonates (≤1 month age) with HSCR who suffered with bowel perforation.

Brief summary: Hirschsprung's disease (HSCR) is a common digestive malformation with radiographic evidence of distal bowel obstruction and clinical signs of abdominal distension, vomiting, constipation, and failure to pass meconium. Bowel perforation (perforated HSCR) is a very serious complication of HSCR, but if this occurs it is most often in the neonatal period. The current study collected information on all cases diagnosed with perforated HSCR from multi-centers in China over 10 years, the aim was to evaluate the clinical features of perforated HSCR, and investigate possible risk factors for perforated HSCR in neonates.


Eligibility criteria: Inclusion Criteria:

* Neonates (≤1 month age)
* Diagnosed with HSCR
* Suffered with bowel perforation

Exclusion Criteria:

* Patients complicated with suspected necrotizing enterocolitis (NEC), imperforate anus (IA), intestinal atresia, and meconium plug syndrome
* Neonates who transferred from outside participating hospitals.

Primary outcomes:
measure: Rate of bowel perforation in neonatal Hirschsprung disease (perforated HSCR)
timeFrame: 14 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04307641: Improving Person Centered Care for Abortion Clients in India
Official title: Strengthening Patient-Centered Accessibility, Respect, and Quality of Care for Abortion Clients in UP, India
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Reproductive Health
Keywords: abortion
person-centered care
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
Collaborators: name: Public Health Foundation of India
First posted: 2020-03-13
Enrollment: 283
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to understand the effect of providing pharmacists in UP, India with additional information about medication abortion.

Detailed description: This study evaluates whether providing pharmacists with additional information about medication abortion can improve abortion person-centered care for women accessing MA at these sites.

Eligibility criteria: Inclusion Criteria:

* Pharmacist providing medication abortion within Lucknow, Kanpur, Unnao
* Agreed to participate

Exclusion Criteria:

* Pharmacists not providing medication abortion within Lucknow, Kanpur, Unnao
* Did not agree to participate

Primary outcomes:
measure: Change in knowledge about medication abortion
timeFrame: baseline compared to 6-months after intervention
Secondary outcomes:
measure: Provider behavior when providing medication abortion (MA) to clients
timeFrame: 3-months post intervention
measure: Interest and satisfaction with intervention
timeFrame: 6-months after intervention
Other outcomes:
Locations:
Study officials:
affiliation: University of California, San Francisco
name: Nadia Diamond-Smith, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00124241: An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B
Official title: A Phase IIb Extension Study of LdT (Telbivudine), Lamivudine or LdT Plus Lamivudine in Patients With Chronic Hepatitis B Who Have Completed Study NV-02B-003
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hepatitis B
Lead sponsor: Novartis
Sponsor class: INDUSTRY
Collaborators: name: Novartis Pharmaceuticals
First posted: 2005-07-27
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is an extension study for patients who have previously completed Idenix Study NV-02B-003. This study is being conducted to compare the safety and effectiveness of treatment beyond 1 year of telbivudine and telbivudine combined with lamivudine, a drug currently approved for the treatment of hepatitis B.


Eligibility criteria: Inclusion Criteria:

* Patient has completed protocol NV-02B-003 without a serious adverse event attributed to study drug
* Patient remains seropositive for hepatitis B surface antigen (HBsAg)

Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Patient is pregnant or breast-feeding
* Patient has signs of decompensated chronic hepatitis B

Other protocol-defined exclusion criteria may apply.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
state: California
city: Toronto
country: Canada
city: Hong Kong
country: China
city: Paris
country: France
Study officials:
References: